Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × pertuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 71 Neoplasms 5 HER2-positive Breast Cancer 5 Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Stomach Neoplasms 2 Pathologic Complete Response 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Locally Advanced Breast Cancer 2 Biliary Tract Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Urinary Bladder Neoplasms 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Metastatic HER2-Positive Breast Cancer 1 Metastatic Breast Cancer With a Isolated Brain Progression 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 Her2-Positive Breast Cancer 1

Interventions

Gemcitabine 8 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Irinotecan 3 Bevacizumab 3 pembrolizumab 2 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Erlotinib Hydrochloride 2 Cisplatin 2 CP protocol 2 tegafur-gimeracil-oteracil 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1 Vemurafenib 1 Transurethral Resection of Prostate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡